Investigation of Trends in Tuberculosis Drug Resistance in Türkiye

Meltem Ayaş; Aylin Suran; Ravel Deniz Saygı; Neval Yurttutan

doi:10.31067/acusaglik.1881966

Investigation of Trends in Tuberculosis Drug Resistance in Türkiye

Abstract

Purpose: The emergence of drug-resistant Mycobacterium tuberculosis complex (MTC) strains poses a significant challenge to global tuberculosis (TB) control efforts. This study aimed to evaluate the trends of primary resistance to first-line anti-tuberculosis drugs among clinical MTC isolates obtained in Türkiye over an eight-year period. Methods: This retrospective study included 408 culture-confirmed MTC isolates collected between 2017 and 2024. Drug susceptibility testing for isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and streptomycin (SM) was performed using the Sensititre MYCOTB MIC plate method. Resistance patterns were analyzed according to demographic characteristics and time period. Results: Resistance to at least one first-line drug was detected in 19.3% of isolates. The highest resistance rate was observed for SM, followed by INH, RIF, and EMB. Multidrug-resistant TB (MDR-TB), defined as resistance to both INH and RIF, was detected in 4.16% of cases. Drug resistance was significantly associated with patient age (p < 0.05), whereas no significant relationship was found with gender. Resistance rates were higher during the COVID-19 pandemic period, although the difference was not statistically significant. Conclusion: Primary resistance among MTC strains remains an ongoing concern in Türkiye. Continuous monitoring of resistance patterns is essential to support effective treatment strategies and tuberculosis control programs.

Keywords

References

1. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
2. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016 Oct 27; 2:16076. doi: 10.1038/nrdp.2016.76.
3. Lin SY, Desmond EP. Molecular diagnosis of tuberculosis and drug resistance. Clin Lab Med. 2014; 34:297-314. doi: 10.1016/j. cll.2014.02.005.
4. Terzi HA, Aydemir Ö, Karakeçe E, Köroğlu M, Altındiş M. Changes in the resistance rates of Mycobacterium tuberculosis complex isolates to anti-tuberculosis drugs over the years: Sakarya experience. Okmeydanı Tıp Derg. 2019; 4:47-56. doi:10.26453/otjhs.441168.
5. Çaycı Y, Avan T, Bilgin K, Birinci A. Evaluation of the susceptibility of Mycobacterium tuberculosis complex isolates from clinical samples to first-line anti-tuberculosis drugs. Van Med J. 2020; 27:155-159. doi:10.5505/vtd.2020.74317.
6. Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. BMJ. 2006; 332:1194-1197. doi:10.1136/ bmj.332.7551.1194.
7. World Health Organization. Types of TB drug resistance [Internet]. Available from: https://www.who.int/teams/global-programme-ontuberculosis- and-lung-health/diagnosis-treatment/treatment-ofdrug- resistant-tb/types-of-tb-drug-resistance. Accessed May 2025.
8. Song WM, Li YF, Ma XB, Liu JY, Tao NN, Liu Y, et al. Primary drug resistance of Mycobacterium tuberculosis in Shandong, China, 2004- 2018. Respir Res. 2019; 20:223. doi:10.1186/s12931-019-1199-3.

9. Zhang H, Yang J, Zhang Z, Hu K, Wu P, Zhang H, et al. Patterns and trends of primary drug-resistant tuberculosis in Chongqing, China, from 2012 to 2020. Medicine (Baltimore). 2023;102: e33230. doi:10.1097/MD.0000000000033230.
10. Turkish Ministry of Health, General Directorate of Public Health. Tuberculosis Diagnosis and Treatment Guideline. Ankara: Ministry of Health; 2019. Available from: https://hsgm.saglik.gov.tr/depo/ birimler/tuberkulozdb/Dokumanlar/Rehberler/Tuberkuloz_Tani_ ve_Tedavi_Rehberi.pdf. Accessed June 2025.
11. Arslan N, Özkarataş MH, Esen N, Özkütük A. Dokuz Eylül Üniversitesi Hastanesi, Mycobacterium tuberculosis kompleks izolatlarının ilk sıra antitüberküloz ilaçlara duyarlılıkları. Turk Mikrobiyol Cemiy Derg. 2021;51(2):172-179. doi:10.5222/TMCD.2021.36449.
12. Baquero-Artigao F, Del Rosal T, Falcón-Neyra L, Ferreras-Antolín L, Gómez-Pastrana D, Hernanz-Lobo A, et al. Update on the diagnosis and treatment of tuberculosis. An Pediatr (Barc). 2023; 98:460-469. doi: 10.1016/j.anpede.2023.03.009.
13. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656-673. doi:10.1111/ resp.13304.
14. Republic of Turkey Ministry of Health, General Directorate of Public Health. Tuberculosis control in Turkey 2021 report. Ankara: Ministry of Health; 2023.
15. Yakupoğulları Y, Otlu B, Tekerekoğlu MS, Polat A. Tüberküloz hastalarından 2014-2022 yılları arasında izole edilen mikobakterilerin anti-tüberküloz ilaç duyarlılıkları. ANKEM Derg. 2023;37(3):74-81. doi:10.54962/ankemderg.1405325.
16. Görgün S, Aydoğdu Ö, Çekiç Cihan Ç, Aydoğdu S, İşler H. Mycobacterium tuberculosis drug resistance and evaluation of the current situation. Turk J Clin Lab. 2024; 15:169-175. doi:10.18663/ tjcl.1441463.
17. Lee EG, Min J, Kang JY, Kim SK, Kim JW, Kim YH, et al. Agestratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study. BMC Infect Dis. 2020 Jun 23;20(1):446. doi: 10.1186/s12879-020-05157-6.
18. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006 Aug 15;194(4):479-85. doi: 10.1086/505877.
19. Bu Q, Qiang R, Fang L, Peng X, Zhang H, Cheng H. Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019. Front Pharmacol. 2023; 14:1156249. doi:10.3389/fphar.2023.1156249.
20. Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia. Trop Dis Travel Med Vaccines. 2018; 4:5. doi:10.1186/ s40794-018-0065-5.
21. Dessalegn M, Daniel E, Behailu S, Wagnew M, Nyagero J. Predictors of multidrug-resistant tuberculosis among adult patients. Pan Afr Med J. 2016;25(Suppl 2):5. doi: 10.11604/pamj.supp.2016.25.2.9203.
22. Madaki S, Mohammed Y, Rogo LD, Yusuf M, Bala YG. Age and gender in drug-resistant tuberculosis. J Glob Antimicrob Resist. 2024; 39:175-183. doi: 10.1016/j.jgar.2024.09.002.
23. López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, Camacho-Ortiz A, Morfin-Otero MDR, Rodríguez-Noriega E et al. Increment antimicrobial resistance during the COVID-19 pandemic. Microb Drug Resist. 2022;28(3):338-345. doi:10.1089/mdr.2021.0231.
24. Rizvi SG, Ahammad SZ. COVID-19 and antimicrobial resistance. Sci Total Environ. 2022;807(Pt 2):150873. doi: 10.1016/j. scitotenv.2021.150873.
25. Silva BPMD, Almeida AS, Sérgio MGM, Gatto TC, Carasek VP, Yamamura M. Drug-resistant tuberculosis and COVID-19. Rev Bras Enferm. 2023;76(Suppl 1): e20220803. doi:10.1590/0034-7167-2022-0803.
26. Ichsan I, Redwood-Campbell L, Mahmud NN, Dimiati H, Yani M, Mudatsir M, et al. Risk factors of MDR-TB and impacts of COVID-19 pandemic on escalating of MDR-TB incidence in lower-middleincome countries: A scoping review. Narra J. 2023 Aug;3(2):e220. doi: 10.52225/narra.v3i2.220.
27. McQuaid CF, McCreesh N, Read JM, Sumner T; CMMID COVID-19 Working Group; Houben RMGJ, et al. The potential impact of COVID- 19-related disruption on tuberculosis burden. Eur Respir J. 2020 Aug 13;56(2):2001718. doi: 10.1183/13993003.01718-2020.
28. Stop TB Partnership. The Impact of COVID-19 on TB Response: A Community Perspective. Geneva: Stop TB Partnership; 2023. Available from: https://www.stoptb.org/sites/default/files/ imported/document/BoardDocs/33/33-06/33-6.2_The_Impact_ of_COVID_on_TB_Response_A_Community_Perspective_0.pdf. Accessed March 5, 2026.
29. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria. Lancet Glob Health. 2022;8: e1132-e1141. doi:10.1016/S2214-109X(20)30288-6.

Details

Primary Language

English

Subjects

Infectious Diseases

Journal Section

Research Article

Authors

Meltem Ayaş ^*
0000-0003-1920-9261
Türkiye

Aylin Suran
0009-0002-3980-8616
Türkiye

Ravel Deniz Saygı
0009-0000-1059-6512
Türkiye

Neval Yurttutan ^*
0000-0002-6198-3296
Türkiye

Publication Date

May 5, 2026

Submission Date

February 4, 2026

Acceptance Date

March 11, 2026

Published in Issue

Year 2026 Volume: 17 Number: April, May, June 2026

DOI

https://doi.org/10.31067/acusaglik.1881966

IZ

https://izlik.org/JA28CM53YL

Cite

RIS / Bibtex

APA

Ayaş, M., Suran, A., Saygı, R. D., & Yurttutan, N. (2026). Investigation of Trends in Tuberculosis Drug Resistance in Türkiye. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, 17(April, May, June 2026). https://doi.org/10.31067/acusaglik.1881966

AMA

1.Ayaş M, Suran A, Saygı RD, Yurttutan N. Investigation of Trends in Tuberculosis Drug Resistance in Türkiye. Acibadem Univ Saglik Bilim Derg. 2026;17(April, May, June 2026). doi:10.31067/acusaglik.1881966

Chicago

Ayaş, Meltem, Aylin Suran, Ravel Deniz Saygı, and Neval Yurttutan. 2026. “Investigation of Trends in Tuberculosis Drug Resistance in Türkiye”. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 17 (April, May, June 2026). https://doi.org/10.31067/acusaglik.1881966.

EndNote

Ayaş M, Suran A, Saygı RD, Yurttutan N (May 1, 2026) Investigation of Trends in Tuberculosis Drug Resistance in Türkiye. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 17 April, May, June 2026

IEEE

[1]M. Ayaş, A. Suran, R. D. Saygı, and N. Yurttutan, “Investigation of Trends in Tuberculosis Drug Resistance in Türkiye”, Acibadem Univ Saglik Bilim Derg, vol. 17, no. April, May, June 2026, May 2026, doi: 10.31067/acusaglik.1881966.

ISNAD

Ayaş, Meltem - Suran, Aylin - Saygı, Ravel Deniz - Yurttutan, Neval. “Investigation of Trends in Tuberculosis Drug Resistance in Türkiye”. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 17/April, May, June 2026 (May 1, 2026). https://doi.org/10.31067/acusaglik.1881966.

JAMA

1.Ayaş M, Suran A, Saygı RD, Yurttutan N. Investigation of Trends in Tuberculosis Drug Resistance in Türkiye. Acibadem Univ Saglik Bilim Derg. 2026;17. doi:10.31067/acusaglik.1881966.

MLA

Ayaş, Meltem, et al. “Investigation of Trends in Tuberculosis Drug Resistance in Türkiye”. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, vol. 17, no. April, May, June 2026, May 2026, doi:10.31067/acusaglik.1881966.

Vancouver

1.Meltem Ayaş, Aylin Suran, Ravel Deniz Saygı, Neval Yurttutan. Investigation of Trends in Tuberculosis Drug Resistance in Türkiye. Acibadem Univ Saglik Bilim Derg. 2026 May 1;17(April, May, June 2026). doi:10.31067/acusaglik.1881966